Curesign

A new way to follow treatment response

Scheduled MRI / CT	Curesign + routine ultrasound
Weeks or months between scans Response is usually confirmed late in a course of treatment.	Weekly, if needed Short ultrasound scans can be repeated as often as once a week, between scheduled MRI or CT.
Late changes of course A treatment that isn't working may continue until the next scan.	Earlier decisions Designed to flag non-response sooner, so oncologists can reconsider treatment earlier.
Mainly size-based Standard response criteria rely on tumor size, which can take time to change.	Beyond size Combines tumor shape and tissue stiffness, measured the same way every time.
Costly and hard to schedule Limited scanner time, and CT adds radiation.	Accessible Built on ultrasound hospitals already use, with no radiation.

Scheduled MRI or CT

Ultrasound measured by Curesign

Treatment startsCourse of treatment

Illustrative. Measuring as often as once a week gives the care team feedback on a treatment while there is still time to change it.

Ultrasound, made measurable

Curesign's software analyzes a standard ultrasound examination that captures both the shape of a tumor and the stiffness of its tissue. It measures the tumor the same way every time and compares each new scan with the ones before, so a change over time reflects the tumor, not the person doing the scan.

Illustrated tumor at scan 1, largest and stiffest — Illustration: one tumor followed across four scans, getting smaller and softer as treatment takes effect.Softer Stiffer

Illustrated tumor at scan 2, slightly smaller — Illustration: one tumor followed across four scans, getting smaller and softer as treatment takes effect.Softer Stiffer

Objective

Size and tissue stiffness are measured automatically and reported as numbers, not impressions.

Comparable

Each scan is lined up with the patient's earlier scans, so change between scans is measured directly.

Accessible

Software only, built on ultrasound that hospitals already use. No radiation, so scans can be repeated as often as care needs.

How it fits into care

Scan

As often as once a week during treatment, a sonographer performs one short, standard ultrasound examination.
Measure

The scan is analyzed automatically. Curesign measures the tumor and compares it with the patient's previous scans.
Decide

The oncologist gets a clear visual report of how the tumor is changing, and uses it alongside everything else they know to continue or adjust treatment.

Who it helps

Patients

Less time on treatments that aren't working, and a quicker path to ones that might.

Oncologists

Regular, objective feedback on whether a treatment is working, between scheduled scans.

Hospitals and health systems

Response monitoring that uses existing ultrasound capacity rather than scarce MRI and CT time.

Drug developers

Earlier, quantitative signals of how tumors respond while new therapies are being developed.

From protocol to patient

Cancer treatment rightly follows evidence-based protocols: a set regimen, a set number of cycles, and response checked at scheduled scans. Precision oncology has made choosing the treatment more personal. Following how each patient responds once treatment starts is the next step.

Protocol-driven care	Personalized, response-guided care
One schedule for everyone Imaging is timed by the protocol, not by how the patient is doing.	Paced to the patient The tumor can be measured as often as once a week throughout treatment.
The plan holds until the next scan Changes usually wait for the scheduled checkpoint.	Adjust along the way Oncologists see the trend between scheduled scans and can reconsider sooner if it isn't working.
Built on averages The regimen reflects how patients responded on average in trials.	Built on the individual Decisions are informed by how this patient's tumor is actually changing.
Precision at the start Biomarkers guide which therapy to choose.	Precision throughout Objective feedback on whether the chosen therapy is working.

The right treatment, sooner.

Every week on a therapy that isn't working is time a patient can't get back. Curesign is turning ultrasound into an objective, repeatable measure of how each tumor responds, giving oncologists earlier and clearer evidence of whether a treatment is working. Our goal is better treatment decisions, fewer side effects from therapies that aren't helping, and better outcomes, with the potential to save lives, wherever patients are treated.

Talk to us

We'd like to hear from oncologists, hospitals, imaging companies and life-science partners who share this goal.

Email Curesign
info@curesign.com

Know sooner whether cancer treatment is working.